FDA is­sues draft guid­ance aimed at curb­ing man­u­fac­tur­ing short­ages

The FDA is hop­ing that its lat­est draft guid­ance will lead to bet­ter in­for­ma­tion about po­ten­tial drug and ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) short­ages from man­u­fac­tur­ers.

The pro­posed draft guid­ance aims to paint a clear­er pic­ture for man­u­fac­tur­ers about giv­ing no­ti­fi­ca­tions for changes in the pro­duc­tion of drugs, bi­o­log­i­cal prod­ucts or APIs, the FDA said in the 17-page doc­u­ment. The move comes as the FDA works to pre­vent and man­age drug short­ages.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER